Next Article in Journal
Crossing Paths in Human Renal Cell Carcinoma (hRCC)
Next Article in Special Issue
Molecular Pathogenesis of Neuromyelitis Optica
Previous Article in Journal / Special Issue
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2012, 13(10), 12665-12709;

What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?

Department of Neurology, Royal Melbourne Hospital, Royal Parade, Parkville VIC 3050, Australia
School of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australia
Department of Neurology, Gold Coast Hospital, 108 Nerang Street, Southport QLD 4215, Australia
Melbourne Brain Centre at the Royal Melbourne Hospital, Department of Medicine, University of Melbourne, Royal Parade, Parkville VIC 3010, Australia
Author to whom correspondence should be addressed.
Received: 2 August 2012 / Revised: 8 September 2012 / Accepted: 12 September 2012 / Published: 4 October 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
Full-Text   |   PDF [554 KB, uploaded 19 June 2014]


Multiple sclerosis is a potentially debilitating disease of the central nervous system. A concerted program of research by many centers around the world has consistently demonstrated the importance of the immune system in its pathogenesis. This knowledge has led to the formal testing of a number of therapeutic agents in both animal models and humans. These clinical trials have shed yet further light on the pathogenesis of MS through their sometimes unexpected effects and by their differential effects in terms of impact on relapses, progression of the disease, paraclinical parameters (MRI) and the adverse events that are experienced. Here we review the currently approved medications for the commonest form of multiple sclerosis (relapsing-remitting) and the emerging therapies for which preliminary results from phase II/III clinical trials are available. A detailed analysis of the molecular mechanisms responsible for the efficacy of these medications in multiple sclerosis indicates that blockade or modulation of both T- and B-cell activation and migration pathways in the periphery or CNS can lead to amelioration of the disease. It is hoped that further therapeutic trials will better delineate the pathogenesis of MS, ultimately leading to even better treatments with fewer adverse effects. View Full-Text
Keywords: multiple sclerosis; treatment; mechanism of action; immunomodulation multiple sclerosis; treatment; mechanism of action; immunomodulation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Buzzard, K.A.; Broadley, S.A.; Butzkueven, H. What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis? Int. J. Mol. Sci. 2012, 13, 12665-12709.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top